Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease

Journal of Family Practice

Volumn 47, Issue 5, 1998, Pages 349-356

  Hunninghake, Donald ^a   Bakker Arkema, Rebecca G ^f   Wigand, James P ^b   Drehobl, Margaret ^c   Schrott, Helmut ^d   Early, James L ^e   Abdallah, Paul ^b   McBride, Scott ^f   Black, Donald M ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Wigand Wasserman Burris Young Med ^*

^c Ctr for Hlth Care Med Associates

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF KANSAS   (United States)

^f PFIZER INC   (United States)

Author keywords

Atherosclerosis; Cholesterol; Coronary heart disease

Indexed keywords

ATORVASTATIN; COLESTIPOL; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS;

EID: 0031772246     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335:1001-9.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995; 333:1301-7.
3. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993; 269:3015-24.
4. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15:678-82.
5. Davidson MM, McKenney JM, Stein EA, et al. Long-term efficacy and safety of atorvastatin compared to lovastatin in hypercholesterolemic patients. Am J Cardiol 1997; 79:1475-81.
6. Bertolini S, Bittolo Bon G, Campbell LM, et al. The efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130:191-7.
7. Remmell PS, Gorder DD, Hall Y, Tillotson JL. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT), I: use of a dietary monitoring tool. JAMA 1980; 76:351-6.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of a centrifuge. Clin Chem 1972; 22:98-101.
9. Feskanich D, Buzzard IM, Welch BT, Asp EH, et al. Comparison of a computerized and manual method of food coding for nutrient intake studies. J Am Diet Assoc 1988; 88:1263-7.
10. Steiner PM, Freidel J, Bremner WF, Stein EA. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Clinics methodology. J Clin Chem Clin Biochem 1981; 19:850.
11. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978; 19:67-76.
12. Lipid and lipoprotein analysis. In: Manual of laboratory operations: LRC program report (NIH) 75-628. US Department of Health, Education and Welfare, 1974, Vol 1.
13. Koren M, Smith D, Hunninghake D, et al. Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. PharmacoEconomics. In press.
14. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100:197-204.
15. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Eng J Med 1995; 332:1125-31.